Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06262477 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
NCT06262477 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 300 participants.
The verdict
NCT06262477, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
Study Summary
The primary objective of the study is to show equivalence in pharmacokinetics (PK) of BIIB800 and Actemra following SC administration of a single dose to healthy male participants. The secondary objective of the study is to evaluate PK over time, clinical safety, pharmacodynamic (PD) profiles and immunogenicity of BIIB800 and Actemra.
Interventions
- DRUG BIIB800
- DRUG Actemra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-01-02 |
| Est. Completion | 2024-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06262477
The ClinicalTrials.gov registry entry for NCT06262477 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BIIB800 is the first listed.
NCT06262477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06262477 about?
NCT06262477 is a clinical study titled "A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants". The primary objective of the study is to show equivalence in pharmacokinetics (PK) of BIIB800 and Actemra following SC administration of a single dose to healthy male participants. The secondary objective of the study is to evaluate PK over time, clinical safety, pharmacodynamic (PD) profiles and im...
What is the current status of trial NCT06262477?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2024-01-02. Estimated completion is 2024-10-04.
What interventions are being tested in trial NCT06262477?
The interventions under investigation include: BIIB800 (DRUG), Actemra (DRUG).
Who is sponsoring clinical trial NCT06262477?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.